186 related articles for article (PubMed ID: 34514091)
21. Recombinant Oncolytic Vaccinia Viruses Expressing Human β-Defensin 2 Enhance Anti-tumor Immunity.
Sun T; Luo Y; Wang M; Xie T; Yan H
Mol Ther Oncolytics; 2019 Jun; 13():49-57. PubMed ID: 31011627
[TBL] [Abstract][Full Text] [Related]
22. High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma.
Delaunay T; Nader J; Grard M; Farine I; Hedwig V; Foloppe J; Blondy T; Violland M; Pouliquen D; Grégoire M; Boisgerault N; Erbs P; Fonteneau JF
Mol Ther Oncolytics; 2020 Sep; 18():573-578. PubMed ID: 32995481
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.
Acuna SA; Ottolino-Perry K; Çako B; Tang N; Angarita FA; McCart JA
Ann Surg Oncol; 2014 Jul; 21(7):2259-66. PubMed ID: 24719018
[TBL] [Abstract][Full Text] [Related]
24. [Oncolytic vaccinia virus expressing CD40L (CD40L-VV) inhibits colorectal cancer cell growth and enhances anti-tumor activity of T cells in tumor-bearing mice].
Liu D; Ma J; Ding B; Zhou H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):602-607. PubMed ID: 34140071
[TBL] [Abstract][Full Text] [Related]
25. Identification of oncolytic vaccinia restriction factors in canine high-grade mammary tumor cells using single-cell transcriptomics.
Cambien B; Lebrigand K; Baeri A; Nottet N; Compin C; Lamit A; Ferraris O; Peyrefitte CN; Magnone V; Henriques J; Zaragosi LE; Giorgetti-Peraldi S; Bost F; Gautier-Isola M; Rezzonico R; Barbry P; Barthel R; Mari B; Vassaux G
PLoS Pathog; 2020 Oct; 16(10):e1008660. PubMed ID: 33075093
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of recombinant oncolytic vaccinia virus with human IL2.
Liu L; Li H; Xu Q; Wu Y; Chen D; Yu F
Open Med (Wars); 2022; 17(1):1084-1091. PubMed ID: 35799600
[TBL] [Abstract][Full Text] [Related]
27. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
28. Single-particle characterization of oncolytic vaccinia virus by flow virometry.
Tang VA; Renner TM; Varette O; Le Boeuf F; Wang J; Diallo JS; Bell JC; Langlois MA
Vaccine; 2016 Sep; 34(42):5082-5089. PubMed ID: 27614781
[TBL] [Abstract][Full Text] [Related]
29. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
[TBL] [Abstract][Full Text] [Related]
30. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence.
Stack J; Haga IR; Schröder M; Bartlett NW; Maloney G; Reading PC; Fitzgerald KA; Smith GL; Bowie AG
J Exp Med; 2005 Mar; 201(6):1007-18. PubMed ID: 15767367
[TBL] [Abstract][Full Text] [Related]
31. The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.
Foloppe J; Kempf J; Futin N; Kintz J; Cordier P; Pichon C; Findeli A; Vorburger F; Quemeneur E; Erbs P
Mol Ther Oncolytics; 2019 Sep; 14():1-14. PubMed ID: 31011628
[TBL] [Abstract][Full Text] [Related]
32. Concurrent expression of
Ma J; Jin C; Čančer M; Wang H; Ramachandran M; Yu D
Mol Ther Oncolytics; 2021 Jun; 21():356-366. PubMed ID: 34141872
[TBL] [Abstract][Full Text] [Related]
33. Deletion of
Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH
EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
35. Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways.
Mejías-Pérez E; Carreño-Fuentes L; Esteban M
Mol Ther Oncolytics; 2018 Mar; 8():27-40. PubMed ID: 29367944
[TBL] [Abstract][Full Text] [Related]
36. Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity.
Jeong SN; Yoo SY
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32344903
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
38. Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro.
Jiang B; Lun X; Hao X; Wang Y; Yin X; Huang D; He W; Wang Z
Biomed Pharmacother; 2017 Nov; 95():1201-1208. PubMed ID: 28931212
[TBL] [Abstract][Full Text] [Related]
39. Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses.
Beattie E; Paoletti E; Tartaglia J
Virology; 1995 Jul; 210(2):254-63. PubMed ID: 7542414
[TBL] [Abstract][Full Text] [Related]
40. Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.
Ottolino-Perry K; Tang N; Head R; Ng C; Arulanandam R; Angarita FA; Acuna SA; Chen Y; Bell J; Dacosta RS; McCart JA
Int J Cancer; 2014 Feb; 134(3):717-30. PubMed ID: 23893655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
